BCDA BioCardia, Inc.
USHealthcareAs of 2026-07-10 16:00
Why BCDA matters now
BioCardia, Inc. (BCDA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.91 with +2.51% on the session and $5.3M in market capitalization; recent performance reads 1-month +1.74% and YTD -22.61%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.3M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -133.5%.
The latest indexable market news headline is "BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Altman Peter filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-9.81
P/S
0.00
EV/EBITDA
-0.69
DCF Value
$0.21
FCF Yield
-133.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-5456.1%
ROA
-454.1%
ROIC
1195.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.3M | $-0.21 |
| Q4 2025 | $0.00 | $-2.0M | $-0.18 |
| FY 2025 | $0.00 | $-8.2M | $-1.23 |
| Q3 2025 | $0.00 | $-1.5M | $-0.24 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.50
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.